What is Outpace Bio?
Operating at the intersection of synthetic biology and oncology, Outpace Bio is dedicated to engineering smarter cell therapies. The company utilizes a sophisticated platform to redesign proteins, enabling T-cells to better navigate the complex tumor microenvironment. This technical capability allows for more precise, potent, and persistent therapeutic interventions. As a key player in the biotech ecosystem, Outpace Bio is moving beyond traditional immunotherapy limitations, aiming to provide curative solutions for patients suffering from hematologic malignancies and solid tumors. Their market position is bolstered by a robust intellectual property portfolio and a clear focus on solving the biological bottlenecks that currently limit the scalability of personalized medicine.
How much funding has Outpace Bio raised?
Outpace Bio has raised a total of $174M across 2 funding rounds:
Series A
$30M
Series B
$144M
Series A (2021): $30M with participation from Mubadala, Civilization Ventures, Playground, Artis Ventures Management Iii, Abstract Ventures, Sahsen Ventures, Lyell Immunopharma, and WRF Capital
Series B (2024): $144M led by RA Capital Management, WRF Capital, and Qatar Investment Authority
Key Investors in Outpace Bio
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing their internal think tank, TechAtlas, to support strategic decision-making.
WRF Capital
Washington Research Foundation (WRF) is a leading early-stage investor focused on transforming innovative ideas into successful businesses in Washington, specializing in life sciences and technology commercialization.
Qatar Investment Authority
Qatar Investment Authority is the sovereign wealth fund of the State of Qatar, managing global financial assets across diverse sectors to support long-term economic development and diversification.
What's next for Outpace Bio?
With the successful closure of its latest financing round, Outpace Bio is well-positioned to accelerate its clinical development pipeline. The strategic capital will likely be deployed to scale manufacturing capabilities and advance its lead candidates through rigorous clinical trials. As the company transitions from a research-heavy entity to a clinical-stage powerhouse, the focus will shift toward validating its synthetic biology platform in human subjects. Investors are closely watching how these engineered immune cells perform in real-world clinical settings, as success here could redefine the standard of care for difficult-to-treat cancers and solidify Outpace Bio's status as a leader in the high-growth cell therapy market.
See full Outpace Bio company page
